Introducing Falcon MLR, Veeva's AI-powered review platform, Hyland described a future in which AI acts less like a piece of ...
MSD has called a halt to three trials of BTK inhibitor nemtabrutinib – added to its pipeline through its $2.7 billion ...
Donald Trump nominated Overton – a White House aide, physician, and vocal opponent of abortion – in the summer. The following ...
Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...
Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...
The takeover deal – worth up to $1.15 billion including $550 million in upfront cash – will upgrade the Dutch biotech's ...
Swiss biotech Windward Bio has raised $175 million in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its TSLP-acting drug for inflammatory respiratory and dermatological ...
Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a ...
Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly valued at around £2.2 billion (€2.6 billion), although financial terms are not ...
Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market. Now, Gilead Sciences and MSD have data on ...
Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...
The team at Hannover Medical School and Ren Ji Hospital who carried out the treatment. An in vivo gene therapy for alpha-1 antitrypsin deficiency (AATD) developed by Chinese biotech YolTech has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results